Vaxart Inc. [NASDAQ: VXRT] surged by $1.57 during the normal trading session on Friday and reaching a high of $10.00 during the day while it closed the day at $8.74. The company report on June 7, 2021 that Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum.
Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that its executive officers, Andrei Floroiu, CEO, and Sean Tucker, CSO, are scheduled to present at the SVB Leerink CybeRx Series: Vaccine Forum on Monday, June 21, 2021 at 1:00 p.m. Eastern Time.
SVB Leerink CybeRx Series: Vaccine Forum.
Vaxart Inc. stock has also gained 27.22% of its value over the past 7 days. However, VXRT stock has inclined by 29.67% in the 3 months of the year. Over the past six months meanwhile, it has gained 17.95% and gained 53.06% year-on date.
The market cap for VXRT stock reached $876.71 million, with 115.42 million shares outstanding and 114.75 million shares in the current float. Compared to the average trading volume of 16.00M shares, VXRT reached a trading volume of 103706405 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Vaxart Inc. [VXRT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VXRT shares is $13.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VXRT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Vaxart Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on June 11, 2021. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $7 to $17. The new note on the price target was released on August 12, 2020, representing the official price target for Vaxart Inc. stock. Previously, the target price had yet another raise to $22, while B. Riley FBR analysts kept a Buy rating on VXRT stock.
The Average True Range (ATR) for Vaxart Inc. is set at 0.77, with the Price to Sales ratio for VXRT stock in the period of the last 12 months amounting to 515.71. The Price to Book ratio for the last quarter was 5.71, with the Price to Cash per share for the same quarter was set at 1.70.
VXRT stock trade performance evaluation
Vaxart Inc. [VXRT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 27.22. With this latest performance, VXRT shares gained by 34.25% in over the last four-week period, additionally plugging by 17.95% over the last 6 months – not to mention a rise of 286.73% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VXRT stock in for the last two-week period is set at 64.42, with the RSI for the last a single of trading hit 70.66, and the three-weeks RSI is set at 60.25 for Vaxart Inc. [VXRT]. The present Moving Average for the last 50 days of trading for this stock 6.70, while it was recorded at 7.66 for the last single week of trading, and 6.87 for the last 200 days.
Vaxart Inc. [VXRT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Vaxart Inc. [VXRT] shares currently have an operating margin of -766.66. Vaxart Inc.’s Net Margin is presently recorded at -796.34.
Return on Total Capital for VXRT is now -35.02, given the latest momentum, and Return on Invested Capital for the company is -38.23. Return on Equity for this stock declined to -47.26, with Return on Assets sitting at -33.98. When it comes to the capital structure of this company, Vaxart Inc. [VXRT] has a Total Debt to Total Equity ratio set at 17.94. Additionally, VXRT Total Debt to Total Capital is recorded at 15.21, with Total Debt to Total Assets ending up at 14.51. Long-Term Debt to Equity for the company is recorded at 14.02, with the Long-Term Debt to Total Capital now at 11.89.
Reflecting on the efficiency of the workforce at the company, Vaxart Inc. [VXRT] managed to generate an average of -$1,150,714 per employee. Receivables Turnover for the company is 2.05 with a Total Asset Turnover recorded at a value of 0.04.Vaxart Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.10 and a Current Ratio set at 15.10.
Earnings per share (EPS) analysis for Vaxart Inc. [VXRT] stock
With the latest financial reports released by the company, Vaxart Inc. posted -0.12/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -100.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VXRT.
Vaxart Inc. [VXRT]: Insider Ownership positions
There are presently around $281 million, or 30.40% of VXRT stock, in the hands of institutional investors. The top three institutional holders of VXRT stocks are: STATE STREET CORP with ownership of 8,486,301, which is approximately -10.15% of the company’s market cap and around 0.60% of the total institutional ownership; VANGUARD GROUP INC, holding 5,477,693 shares of the stock with an approximate value of $47.88 million in VXRT stocks shares; and BLACKROCK INC., currently with $47.35 million in VXRT stock with ownership of nearly 9.751% of the company’s market capitalization.
Positions in Vaxart Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 89 institutional holders increased their position in Vaxart Inc. [NASDAQ:VXRT] by around 5,177,950 shares. Additionally, 66 investors decreased positions by around 8,574,074 shares, while 21 investors held positions by with 18,349,004 shares. The mentioned changes placed institutional holdings at 32,101,028 shares, according to the latest SEC report filing. VXRT stock had 42 new institutional investments in for a total of 1,137,314 shares, while 24 institutional investors sold positions of 4,878,039 shares during the same period.